ClinicalTrials.gg
CompletedNCT06550128Updated Sep 15, 2026

Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB).

A Phase 2 interventional study of AHB-137 (24 weeks) and AHB-137 and Placebo in Hepatitis B, Chronic, sponsored by Ausper Biopharma Co., Ltd.. Completed at 6 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by Ausper Biopharma Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing Hepatitis B Virus Antisense Oligonucleotide AHB-137 in Hepatitis B, Chronic — 6 open to participants now, 8 under way, 1 of them phase 3. Hepatitis B Virus Antisense Oligonucleotide AHB-137 · Hepatitis B, Chronic.

Enrollment
6th of 11
86 · median 86
Started
2024
the only one that year
Phase 2
7 of 11
5 open now
Registered
3rd of 11
by date
Lead sponsor
8 of 11
Ausper Biopharma Co., Ltd.

Among the 11 studies testing Hepatitis B Virus Antisense Oligonucleotide AHB-137 in Hepatitis B, Chronic, this one is the 6th largest by enrollment, is the only one that started in 2024, is one of 7 in phase 2, and was the 3rd registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

6 of the 11 studies testing Hepatitis B Virus Antisense Oligonucleotide AHB-137 in Hepatitis B, Chronic are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About Hepatitis B Virus Antisense Oligonucleotide AHB-137

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing Hepatitis B Virus Antisense Oligonucleotide AHB-137 in Hepatitis B, Chronic, or all of them as a file.
02

Study summary

AB-10-8003 is a randomized, multi-center phase II study to evaluate the efficacy and safety of AHB-137 in subjects with HBeAg-negative CHB under stable NA treatment.

Read the detailed description

The study is to evaluate the efficacy and safety of AHB-137 in HBeAg-negative CHB subjects. The total duration of the study, including screening phase, treatment phase and follow-up phase.

03

Conditions studied

  • Hepatitis B, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants voluntarily participate in the study, and sign the Form (ICF) prior to screening, able to complete the study and discontinue their NA therapy according to the protocol;
  2. At least 18 years old at the time of signing of the informed consent;
  3. (BMI) between 18 to 32 kg/m\^2(inclusive) ;
  4. Participants who are envelop antigen (HBeAg) negative during screening;
  5. Participants whose serum HBsAg positive for at least 6 months prior to screening;
  6. Participants who have stable on NA therapy at least 6 months prior to screening;
  7. Participants with HBsAg concentration >100 IU/mL and≤3000 IU/mL, HBV DNA\<100 IU/mL;
  8. Participants with (ALT)≤ 2x (ULN);
  9. For women of , she should be non-pregnant or non-lactating during screening, and participants (and partners) are willing to take effective measures from the screening until the last visit or at least 6 months after the last dosing.

Exclusion criteria

Exclusion Criteria:

  1. Clinical significant abnormalities except Chronic infection, such as acute coronary syndrome within 6 months before screening, evidence of major surgery, major or unstable heart disease, bleeding tendency or significant coagulation disorder within 3 months before screening;
  2. Any liver diseases, including but not limited to hepatitis caused by other pathogenic infections, hemochromatosis, Wilson disease, primary biliary cirrhosis, liver diseases, alcoholic liver disease, severe non-alcoholic fatty liver disease, Drug-induced liver injury, etc.;
  3. Participants with severe infection requiring intravenous anti-infection treatment 1 month before randomization;
  4. Active , (HIV) positive, syphilis positive;
  5. Liver stiffness measurement (LSM) > 9.0 kPa when screening;
  6. Diagnosed or suspected hepatocellular carcinoma;
  7. The laboratory examination results are obviously abnormal;
  8. History of vasculitis or signs and symptoms of potential vasculitis;
  9. History of extrahepatic disease that may be related to HBV immune status;
  10. Administration of within 3 months prior to screening, except for short-term use (≤2 weeks) or topical/inhaled . Administration of immunomodulators (thymosin) and cytotoxic drugs within 6 months prior to the first study intervention or have a history of vaccination within 1 month prior to screening or planned administration during the study.
  11. Administration of any Interferon within 6 months prior to screening;
  12. History of malignant tumor within the past 5 years;
  13. Any suspicion of drug component allergy, or allergic constitution (various drug and food allergy, and judged by the investigator to be clinically significant) in participants;
  14. Participants who have significant trauma or major surgery within 3 months before screening, or plan to perform surgery during the study;
  15. Blood donation or blood loss more than 400 mL within 12 weeks before screening; Blood transfusion; Blood donation or blood loss not less than 200 mL within 1 month before screening;
  16. Concurrently participating in another clinical study, or received an product within the following time period prior to the first dosing day in the current study: 5 half-lives or twice the duration of the biological effect of the study treatment or 90 days;
  17. Any oligonucleotide or siRNA treatments within 12 months prior to first dosing;
  18. Any other circumstances or conditions for which the investigator considers that the participants are inappropriate to participate in the study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
86 participants (actual)

Study arms

  • Experimental
    AHB-137 (24 weeks)

    Drug: AHB-137 (24 weeks)

  • Placebo comparator
    Placebo

    Drug: AHB-137 and Placebo

  • Experimental
    AHB-137 (16 weeks)

    Drug: AHB-137 (16 weeks)

Interventions

  • AHB-137 injection will be administered subcutaneously.

  • DrugAHB-137 and Placebo

    AHB-137and placebo will be administered subcutaneously.

  • AHB-137 injection will be administered subcutaneously.

06

What researchers measure

Primary outcomes

  1. Proportion of participants achieving HBsAg < limit of detection (LOD) 0.05 International Unit/mL (IU/mL) and HBV DNA < lower limit of quantitation (LLOQ) with or without anti-HBs seroconversion at the end of treatment.

    Time frame: Up to 24 weeks

Secondary outcomes

  1. Proportion of participants achieving HBsAg lower than LOD and HBV DNA lower than LLOQ , regardless of whether HBsAg seroconversion is observed

    Time frame: At 8 weeks

  2. Proportion of participants meeting NA treatment discontinuation criteria.

    Time frame: Up to 48 weeks

  3. Changes of the score of hepatitis B quality of life instrument (HBQOL) compared with baseline

    This scale has 31 items, including 7 dimensions: psychological status, expected anxiety, vitality, shame, infectivity, health vulnerability, and viral response. Each item is scored on a 5-point scale, with higher scores indicating a more severe impact of hepatitis B on quality of life.

    Time frame: Up to 72 weeks

  4. Percentage of participants with different levels of HBsAg reduction compared with baseline

    Time frame: Up to 72 weeks

  5. Serum levels of HBV DNA, HBsAg, highly sensitive HBsAg, HBcrAg, HBV RNA, HBsAb, HBeAb and HBsAg-HBsAb.

    Time frame: Up to 72 weeks

  6. The time from the discontinuation of NA treatment to virological relapse

    Time frame: Up to 72 weeks

  7. The time from the discontinuation of NA treatment to clinical relapse

    Time frame: Up to 72 weeks

  8. Sequencing of the Viral DNA and/or viral RNA analysis for detection of drug resistance of AHB-137

    Time frame: Up to 24 weeks

  9. Safety: number of participants with adverse events (TEAEs), serious adverse events (SAE) and clinically significant examination results, including laboratory examination, electrocardiogram (ECG) examination, physical examination and vital signs

    Time frame: Up to 72 weeks

  10. Immunogenicity: number and percentage of participants with detectable anti-drug antibodies (ADA)

    Time frame: Up to 72 weeks

  11. Changes of cytokine levels compared with baseline

    Time frame: Up to 72 weeks

  12. The pharmacokinetic profile of AHB-137: Maximum concentration (Cmax) of AHB-137 in plasma

    Time frame: Up to 72 weeks

  13. The pharmacokinetic profile of AHB-137: Area under the concentration-time curve (AUC) of AHB-137

    Time frame: Up to 72 weeks

  14. Plasma concentrations of AHB-137

    Time frame: Up to 72 weeks

  15. Proportion of participants maintaining sustained response.

    Time frame: Up to 72 weeks

07

Study locations

6 sites
  • Mengchao Hepatobiliary Hospital of Fujian Medical University
    Fuzhou, Fujian, China
  • The third People's Hospital of Zhenjiang
    Zhenjiang, Jiangsu, China
  • Beijing Friendship Hospital, Capital Medical University
    Beijing, China
  • The Second Affiliated Hospital of Chongqing Medical University
    Chongqing, China
  • Nanfang Hospital, Southern Medical University
    Guangzhou, China
  • The First Hospital of Jilin University
    Jilin City, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2024 to primary completion in May 2025, 10 months.

Of 75 industry-sponsored phase 2 interventional studies under Hepatitis B, Chronic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 39. This study's 10 months is below that.

Counting every sponsor, half of 87 studies reached it within 23 months; a quarter within 16 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2024
First posted
Aug 12, 2024
StartActual
Jul 10, 2024
Primary completionActual
May 26, 2025
CompletionActual
Jan 26, 2026
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06550128
Responsible party
Sponsor
First posted
Aug 12, 2024
Start date
Jul 10, 2024
Primary completion
May 26, 2025
Completion
Jan 26, 2026
Last update
Sep 15, 2026

Study contacts

Junqi Niu
principal investigator · The First Hospital of Jilin University
Jinlin Hou
principal investigator · Nanfang Hospital, Southern Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hepatitis B Virus Antisense Oligonucleotide AHB-137

Start the discussion